Dr. David R. Blair, MD, PHD
Medical Genetics (Clinical Genetics (M.D.) Physician)
At a glance
- In the NPI registry since
- 2017
Licensed in California since 2018, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Genetics (M.D.) Physician primary
CA license A159073 (first issued 2018; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fabrazyme (agalsidase beta) | 19 |
| Vpriv (velaglucerase alfa) | 12 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in San Francisco, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 7 payments worth $1,484 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $1,484 |
|---|
| Travel and Lodging | $1,475 |
|---|---|
| Food and Beverage | $9.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Jan 9, 2025 | Travel and Lodging travel to TARRYTOWN, NY · in-kind | $800 |
| Regeneron Pharmaceuticals, Inc. Jan 14, 2025 | Travel and Lodging travel to TARRYTOWN, NY · in-kind | $210 |
| Regeneron Pharmaceuticals, Inc. Jan 14, 2025 | Travel and Lodging travel to TARRYTOWN, NY · in-kind | $181 |
| Regeneron Pharmaceuticals, Inc. Jan 15, 2025 | Travel and Lodging travel to TARRYTOWN, NY · in-kind | $168 |
| Regeneron Pharmaceuticals, Inc. Jan 15, 2025 | Travel and Lodging travel to TARRYTOWN, NY · in-kind | $89.71 |
| Regeneron Pharmaceuticals, Inc. Jan 9, 2025 | Travel and Lodging travel to TARRYTOWN, NY · in-kind | $25.50 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $20,015 in research payments for these studies, mostly to the institutions running them.
- BMN 111-902
BioMarin Pharmaceutical Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.